SuperBac Biotechnology Solutions to go public via merger with XPAC Acquisition in a $500m deal.

SuperBac Biotechnology Solutions, a biotech company in Brazil, agreed to go public via merger with XPAC Acquisition, a publicly-traded special purpose acquisition company, in a $500m deal. "We believe that our target segments within the biotechnology market have significant potential to expand in the coming years, and that with this business combination, SuperBac is very well positioned to capitalize on growth opportunities. We understand that innovation and technology play a strategic role in driving sustainable growth and redefining the future of biotechnology, and SuperBac is at the forefront of this movement," Luiz Chacon, SuperBac Founder and CEO.